Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Squamous-cell carcinomas of the lung (SQCLCs) are defined by unique clinicopathological
and molecular characteristics that have evolved substantially over time. Historically, these …

Squamous cell lung cancer (SCC) represents an area of unmet need in lung cancer
research. For the past several years, therapeutic progress in SCC has lagged behind the …

Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is
challenging to treat because of specific clinicopathologic characteristics, which include older …

Abstract The KEAP1-NFE2L2 pathway is an important modulator of cell homeostasis.
Mutations in this pathway are common in NSCLC and have been associated with enhanced …

There have been significant advances in the understanding of the biology and treatment of
non–small-cell lung cancer (NSCLC) during the past few years. A number of molecularly …

The outcomes of patients with SCLC have not yet been substantially impacted by the
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …

Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …

Therapy for advanced non-small-cell lung cancer has developed significantly with new
awareness of histologic subtype as an important factor in guiding treatment and the …